Medical Xpress (09.11.2013)
Aids Weekly Plus
Researchers at the Department of Immunodermatology at the Medical University of Vienna have produced a new human papillomavirus (HPV) vaccine, which will protect against more types of HPV infection. The group, led by Reinhard Kirnbauer, inventor of the existing HPV16 vaccine, collaborated with working groups from the Vienna University of Veterinary Medicine, University of Malmö, and the Johns Hopkins University in Baltimore.
The current HPV vaccines have two to four antigens. For the new vaccine, researchers used an individual new antigen (RG1-VLP) from HPV’s main capsid protein L1 and auxiliary capsid protein L2. In the pre-clinical study, the vaccine demonstrated significantly wider efficacy in combatting high- and low-risk types of HPV, whereas the current vaccines focus on high-risk types. This vaccine also protected against HPV types that affected the skin, causing hand and foot warts and flat warts, mostly in children, but also in adults. These warts could pose significant problems, particularly for immunosuppressed individuals.
The researchers viewed the administration of this vaccine to children as means of preventing skin warts in childhood and protecting them from genital HPV as they grew older.
The full report, “Efficacy of RG1-VLP Vaccination Against Infections with Genital and Cutaneous Human Papillomaviruses,” was published online in the Journal of Investigative Dermatology (2013; doi: 10. 1038/jid.2013.253).